Disappointing trials from XBiotech, Merrimack Pharmaceuticals, and NewLink Genetics have earned the market's ire. But are their declines overdone?
News & Analysis: Xbiotech
Investors are focused on the wrong data.
A European approval seems unlikely.
Without much to go on, investors wonder how well the biotech's colon-cancer drug Xilonix works.
Positive data despite clinical trial irregularities.